Clinical validation study of urinary clusterin and EGF in patients with chronic kidney disease

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507449-27-00

Enrollment

115

Registered

2024-06-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Brief summary

Between-group comparison of the change in albuminuria (UACR) from baseline (randomization) to week 36.

Detailed description

Between-group comparison of the change in eGFR from 1) week 16 to week 64 2) baseline to week 64 3) baseline to week 66, To have developed a communication tool at the end of the study that can instruct patients and healthcare professionals about using biomarker-guided treatment., Between-group comparison of the change in KidneyIntelX score from baseline to week 36.

Interventions

DRUGFINERENONE

DRUGDAPAGLIFLOZIN

DRUGAMBRISENTAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Between-group comparison of the change in albuminuria (UACR) from baseline (randomization) to week 36.	—

Secondary

Measure	Time frame
Between-group comparison of the change in eGFR from 1) week 16 to week 64 2) baseline to week 64 3) baseline to week 66, To have developed a communication tool at the end of the study that can instruct patients and healthcare professionals about using biomarker-guided treatment., Between-group comparison of the change in KidneyIntelX score from baseline to week 36.	—

Countries

Denmark, Germany, Italy, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026